BLX 0856
Alternative Names: BLX-0856Latest Information Update: 06 Jul 2023
At a glance
- Originator Biolexis Therapeutics
- Class Anti-inflammatories; Antihyperglycaemics; Antineoplastics; Cardiovascular therapies; Small molecules
- Mechanism of Action AMP activated protein kinase stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Cancer; Cardiovascular disorders; Inflammation; Type 2 diabetes mellitus
Most Recent Events
- 20 Jun 2023 Preclinical trials in Cancer in USA (unspecified route) before June 2023 (Biolexis Therapeutics pipeline, June 2023)
- 20 Jun 2023 Preclinical trials in Cardiovascular disorders in USA (unspecified route) before June 2023 (Biolexis Therapeutics pipeline, June 2023)
- 20 Jun 2023 Preclinical trials in Inflammation in USA (unspecified route) before June 2023 (Biolexis Therapeutics pipeline, June 2023)